跳至主要内容
临床试验/NCT00301106
NCT00301106终止1 期

Phase I Trial of Adenoviral Vector Delivery of the Human Interleukin-12 cDNA by Intratumoral Injection in Patients With Metastatic Breast Cancer to the Liver

Max Sung1 个研究点 分布在 1 个国家目标入组 2 人开始时间: 2005年10月最近更新:
适应症

试验速览

阶段
1 期
状态
终止
发起方
入组人数
2
试验地点
1
主要终点
Toxicity

研究概览

简要总结

RATIONALE: Biological therapy using a gene-modified virus that can make interleukin-12 may help the body build an effective immune response to kill tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of a gene-modified virus that can make interleukin-12 in treating women with breast cancer that has spread to the liver.

详细描述

Direct intratumoral injection of metastatic hepatic tumors using an adenoviral vector expressing the human recombinant interleukin-12 gene (Adv.RSV-hIL12, also termed ADV-hIL-12).

OBJECTIVES:

  • Study the toxicity of escalating doses of adenoviral vector expressing the human recombinant interleukin-12 gene, administered by percutaneous intratumoral injection, in women with liver metastasis secondary to breast cancer.
  • Determine tumor responses produced by this regimen.
  • Determine immune responses induced by this regimen.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Toxicity

时间窗: up to 15 days

Serial monitoring of tumor necrosis factor alpha (TNFα) levels

次要结局

  • Tumor Response(up to 2 months)
  • IFNγ levels Immune response(up to 2 months)
  • Immune response(up to 2 months)
  • IL12 level Immune response(up to 2 months)

研究者

发起方
Max Sung
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Max Sung

Associate Professor

Icahn School of Medicine at Mount Sinai

研究点 (1)

Loading locations...

相似试验